Penbraya Kit
NDC Package 0069-0600-01
Package Information
Penbraya (meningococcal groups a, b, c, w, and y vaccine) kits is pENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. This formulation utilizes a kit delivery system. Marketed by Pfizer Laboratories Div Pfizer Inc, this product is identified by NDC 0069-0600 and is authorized under FDA application BLA125770.
Identification & Billing
- RxCUI: 2670559 - Meningococcal (Groups A,B,C,Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine 0.5 ML Injection
- RxCUI: 2670559 - 0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML Injection
- RxCUI: 2670559 - Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 5 MCG / Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.06 MG / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.06 MG / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 5 MCG / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 5 MCG / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 5 MCG per 0.5 ML Injection
- RxCUI: 2670566 - PENBRAYA vaccine 0.5 ML Injection
- RxCUI: 2670566 - 0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.01 MG/ML Injection [Penbraya]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0069 - Pfizer Laboratories Div Pfizer Inc
- 0069-0600 - Penbraya
- 0069-0600-01 - 1 KIT in 1 CARTON / 1 KIT in 1 KIT (0069-0600-99) * .5 mL in 1 SYRINGE (0069-0332-01) * .5 mL in 1 VIAL, GLASS (0069-0271-01)
- 0069-0600 - Penbraya
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0069-0600). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0069-0600-01 identifies a specific commercial package of 1 kit in 1 carton / 1 kit in 1 kit (0069-0600-99) * .5 ml in 1 syringe (0069-0332-01) * .5 ml in 1 vial, glass (0069-0271-01) of Penbraya, a vaccine label labeled by Pfizer Laboratories Div Pfizer Inc. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pfizer Laboratories Div Pfizer Inc on November 27, 2023. The current certification is valid through December 31, 2027.
How is this Pfizer Laboratories Div Pfizer Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00069060001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
